ArticleJournal of cancer research and clinical oncology2021
Anti-tumour effect of neo-antigen-reactive T cells induced by RNA mutanome vaccine in mouse lung cancer.
Article in Journal of cancer research and clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Lipid nanoparticle delivery of circle RNA vaccine induces potent immune responses.Scientific reports · 2026Article
- RNA-based cancer vaccines: mechanisms, clinical progress, and translational challenges.Immunologic research · 2025Review
- Reversing the "cold" tumor microenvironment: the role of neoantigen vaccines in prostate cancer.Journal of translational medicine · 2025Article
- RNA sequencing enables neoantigen discovery and vaccine validation in breast and lung cancer.Frontiers in immunology · 2025Article
- Delivery of IL-12 by neoantigen-reactive T cells promotes antitumor immunity in murine osteosarcoma mode.Immunotherapy advances · 2025Article
- Niraparib plays synergistic antitumor effects with NRT in a mouse ovarian cancer model with HRP.Translational oncology · 2024Article
- Advances and applications of RNA vaccines in tumor treatment.Molecular cancer · 2024Review
- [Antitumor Study of Neoantigen-reactive T Cells Co-expressing IL-7 and CCL19 in Mouse Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Article
- Evaluation of the antitumor effect of neoantigen peptide vaccines derived from the translatome of lung cancer.Cancer immunology, immunotherapy : CII · 2024Article
- Nanomaterial Delivery Vehicles for the Development of Neoantigen Tumor Vaccines for Personalized Treatment.Molecules (Basel, Switzerland) · 2024Review
- Review
- Antitumor effect of neoantigen-reactive T cells combined with PD1 inhibitor therapy in mouse lung cancer.Journal of cancer research and clinical oncology · 2023Article
- Transplantable Murine Tumors in the Studies of Peptide Antitumor Vaccines.Oncology reviews · 2023Review
- Neoantigens and their potential applications in tumor immunotherapy.Oncology letters · 2022Review
- Mutant and non-mutant neoantigen-based cancer vaccines: recent advances and future promises.Exploration of targeted anti-tumor therapy · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 1 country.
Funding
Abstract
purposeMutation-specific T-cell response to epithelial cancers and T-cell-based immunotherapy has been successfully used to treat several human solid cancers. We aimed to investigate the anti-tumour effect of neo-antigen-reactive T(NRT) cells induced by RNA mutanome vaccine, which may serve as a feasible and effective therapeutic approach for lung cancer.
methodsWe predicted candidate neo-antigens according to the mutant gene analysis by sequencing the mouse Lewis cells and C57BL/6 mouse tail tissue. RNA vaccine was prepared with the neo-antigens as the template. We assessed antitumor efficacy, cytokine secretion and pathological changes after adoptive transfer of NRT cells in vitro and vivo experiments.
resultsWe identified 10 non-synonymous somatic mutations and successfully generated NRT cells. The percentage of T-cell activation proportion was increased from 0.072% in conventional T cells to 9.96% in NRT cells. Interferon-γ secretion augmented from 17.8 to 24.2% as well. As an in vivo model, adoptive NRT cell infusion could promote active T-cell infiltration into the tumour tissue and could delay tumour progression.
conclusionNRT cells induced by RNA mutanome vaccine exert a significant anti-tumour effect in mouse lung cancer, and adoptive NRT cell therapy might be considered a feasible, effective therapeutic approach for lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.